Danaher Up Over 6%, On Track for Largest Percent Increase Since November 2022 — Data Talk
Danaher Corporation (DHR) is currently at $251.52, up $15.44 or 6.54%
--Would be highest close since March 22, 2024, when it closed at $254.80
--On pace for largest percent increase since Nov. 10, 2022, when it rose 8.47%
--Currently up two consecutive days; up 6.8% over this period
--Best two day stretch since the two days ending Jan. 11, 2023, when it rose 7.36%
--Up 0.72% month-to-date; on pace for best month since Feb. 2024, when it rose 5.51%
--Up 8.72% year-to-date
--Down 14.64% from its all-time closing high of $294.66 on Sept. 3, 2021
--Up 22.31% from 52 weeks ago (April 25, 2023), when it closed at $205.63
--Down 1.82% from its 52-week closing high of $256.19 on March 4, 2024
--Up 35.88% from its 52-week closing low of $185.10 on Oct. 30, 2023
--Traded as high as $256.72; highest intraday level since March 6, 2024, when it hit $257.08
--Up 8.74% at today's intraday high; largest intraday percent increase since July 21, 2022, when it rose as much as 9.2%
--Best performer in the S&P 500 today
All data as of 9:59:45 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 23, 2024 10:17 ET (14:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?